Össur hf: CEO Retirement and Succession Plan
STOCKHOLM, Dec. 10, 2021 /PRNewswire/ -- Jon Sigurdsson to retire after 26 years as Össur President and CEO, Sveinn Sölvason appointed President and CEO successor Jon Sigurdsson has decided to retire from his position as President and CEO of Össur. The Board of Directors has appointed Össur CFO, Sveinn Sölvason, to succeed as President and CEO effective 1 April 2022....
Ascletis Announces First Patient Dosed in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
HANGZHOU and SHAOXING, China, Jan. 23, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) today announces the dosing of the first patient in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma (rGBM). ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN), a key enzyme which regulates de...
Impact Therapeutics Announces Completion of Series D1 Financing
SHANGHAI, March 14, 2022 /PRNewswire/ -- IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, announced the successful completion of its Series D1 financing. Institutional investors that participated in this round include new investors Dingxin Capital, CCBT, C&D EMERGING CAPITAL, Bestride, Exome Asset Management led by Sam Isaly, along...
First in North America: Jolly Good Hosts Clinical VR Multi Seminar in Boston, Aiming for Mass Production of UGC Medical VR
At the Boston Convention Center on Tuesday, October 25, 2022 TOKYO, Oct. 13, 2022 /PRNewswire/ -- Jolly Good Inc. (Chuo-ku, Tokyo, CEO: Kensuke Joji, hereinafter referred to as "Jolly Good") will hold a large-scale seminar on clinical training VR produced by the UGC* medical VR platform "JOLLYGOOD+" (Jolly Good Plus) on Tuesday, October 25, 2022, in Boston in the U.S....
CIVCO Radiotherapy and Qfix Showcase as One Company at ESTRO 2023
CORALVILLE, Iowa, May 8, 2023 /PRNewswire/ -- CIVCO Radiotherapy and Qfix, now together as one company, will exhibit their innovative and patented solutions during the annual ESTRO Congress in Vienna, Austria, 12-16 May 2023. The company encourages attendees to visit booth #200 to experience many of these solutions firsthand. Live product demonstrations will include the Encompass™ SRS Immobilization System,...
BIORCHESTRA will present data on the therapeutic efficacy of their proprietary ASO against pathological miRNA, a key modulator of neuroinflammation and neurodegeneration, at the CTAD Meeting in Boston
BOSTON, Nov. 5, 2021 /PRNewswire/ -- South Korean bio-venture BIORCHESTRA Co. Ltd., is an RNA therapeutics firm focused on neurodegeneration. BIORCHESTRA discovered a disease-associated microRNA that was found to be significantly up-regulated in samples from Alzheimer's disease patients. It then conducted gain-of-function studies and discovered the over-expressed miRNA may be an underlying cause of the disease, deciding to develop...
Research into gut microbiome-autism link reveals new perspective in collaborative Austism CRC study
BRISBANE, Australia, Nov. 12, 2021 /PRNewswire/ -- Results published in Cell, led by Mater Research and The University of Queensland, show that dietary restriction drives microbiome diversity changes in autistic individuals. In the largest study in the field to date, researchers analysed stool samples using Microba's metagenomic analysis, alongside other clinical and...
CARsgen Announces CAR T-cell Product Candidate CT041 Granted PRIME Eligibility by the EMA
SHANGHAI, Nov. 15, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) eligibility to CT041, an autologous CAR T-cell product candidate against the claudin18.2 protein (CLDN18.2) for the...
Sofwave™ Announces FDA clearance of New Lifting Indications for Eyebrow, Sub-Mental (beneath the chin) and Neck Facial Areas
The new indications include Eyebrow lifts and lifting of Lax tissue of the Submental and Neck Areas 80% of patients participating in a multi-site clinical trial saw improvement in just 12 weeks TUSTIN, Calif., Nov. 16, 2021 /PRNewswire/ -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical...
Novo Nordisk among the top 3 Best Places to Work in Singapore for 2021
Singapore, Dec. 20, 2021 Novo Nordisk Singapore, an affiliate of the global healthcare company with more than 95 years of innovation and leadership in diabetes care, has recently been recognized among the top 3 Best Places to Work for 2021. During the assessment, the company received outstanding scores across several aspects of their workplace such as leadership, teamwork and relationships,...
